




Myelophthestic marrow involved by breast cancer and acute myeloid leukemia

William Shomali and Jason Gotlib, Stanford University School of Medicine



A 53-year-old woman was admitted with right thigh pain. She was diagnosed with estrogen receptor (ER)- and progesterone receptor (PR)-positive stage III adenocarcinoma of the left breast 3 years before. She was treated with lumpectomy and adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and radiotherapy, but declined hormonal therapy. A right hip radiograph showed multiple lytic lesions, and positron emission tomography/computed tomography imaging confirmed widespread bony lesions. A complete blood count revealed a white blood cell count of $25 \times 10^9/L$ with 20% blasts, a hemoglobin count of 11.1 g/dL, and a platelet count of $52 \times 10^9/L$. Bone marrow touch preparation (panel A; Wright's stain, original magnification $\times 400$) and core biopsy (panel B; hematoxylin and eosin stain, original magnification $\times 40$) were effaced by myeloblasts (solid arrows) and

infiltrating adenocarcinoma arranged in clusters, ducts, and cords (dashed arrows) that were ER (panel C, dashed arrow; original magnification $\times 200$) and PR positive and Her2 negative by immunohistochemistry. Cytogenetics revealed $t(9;11)(p22;q23)$ and monosomy 7. Fluorescent in situ hybridization was positive for an *MLL* rearrangement. The patient was started on an aromatase inhibitor for her metastatic breast cancer and hypomethylating therapy for her acute myeloid leukemia (AML).

Rearrangements of the *MLL* (or *KMT2A*) gene are frequently seen in therapy-related AML after treatment with topoisomerase II inhibitors with a short latency of 2 to 3 years as compared with AML induced by alkylating agents, which has a latency of 5 to 7 years.



For additional images, visit the ASH Image Bank, a reference and teaching tool that is continually updated with new atlas and case study images. For more information, visit <http://imagebank.hematology.org>.



blood[®]

2018 131: 1036

doi:10.1182/blood-2017-10-809921

Myelophthisic marrow involved by breast cancer and acute myeloid leukemia

William Shomali and Jason Gotlib

Updated information and services can be found at:

<http://www.bloodjournal.org/content/131/9/1036.full.html>

Articles on similar topics can be found in the following Blood collections

[BloodWork](#) (602 articles)

[Free Research Articles](#) (4951 articles)

[Myeloid Neoplasia](#) (1801 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>